FRANKFURT, Oct 25 (Reuters) - Sanofi's finance

chief on Friday said the company won't be affected by Novo

Nordisk's controlling shareholder's decision to

acquire contract drug manufacturer Catalent ( CTLT ), adding the

deal made sense for its rival.

"They desperately need capacity so it makes sense for them,"

Sanofi CFO Francois-Xavier Roger said in a media call after the

release of third-quarter results.

He added Novo paid a "very heavy price to get access to the

capacity", given very strong demand for weight-loss drugs.

Swiss drugmaker Roche on Wednesday joined peer Eli

Lilly ( LLY ) in voicing concern over the planned Catalent ( CTLT )

takeover, saying it could hit competition in the booming

weight-loss drug industry.